The stock of Isoray Inc (ISR) closed the recent trading session at $0.35, 3.76% more than the previous trading session. On the last check, the stock of ISR remained bearish in the after-market, losing 6.54% to $0.33. Isoray published the performance for the Q2 of the financial year 2022. Isoray also filed form 8-K with the SEC on February 08, 2022. The Form 8-K is referred to the declaration of quarterly financial performance.
ISR Q2 of FY22
Isoray Inc published the performance of Q2 of FY22 on 08 February 2022. The Q2 concluded on 31 December 2021. The main points are
- The sales of ISR expanded by 19% from $2.36 million in Q2 of FY21 to $2.82 million in Q2 of FY22.
- Also, the financial gain grew by 4.5%. The profit in Q2 of FY22 was $1.22 million against to $1.17 in the quarter year-ago.
- Moreover, the operating cost also expanded by 40% from $2.4 million in Q2 of fiscal 2021 versus $2.86 million in Q2 of fiscal 2022.
- Further, Isoray reported a total loss of $1.60 million in Q2 of FY22 versus $0.87 million in Q2 of FY21.
- The diluted loss of $0.01 per share.
- Also, the stockholders’ equity at the end of Q2 of FY22 was $64.4 million.
- ISR concentrates on prostrate brachytherapy. The sales for prostrate therapy in Q2 of FY22 grew by 13%.
CEO Remarks
The CEO of Isoray Inc (ISR), Lori Woods, commented that this quarter addresses the third consecutive quarter of YoY growth. Further, she stated that they are convinced that the procedures they have been executing are working and will keep on having a positive effect.
Moreover, Ms. Wood concluded that Isoray is very much situated to speed up its development as markets bounce back from the continuous impacts of the pandemic.
About ISR
Isoray Inc. is a clinical organization and the sole maker of Cesium brachytherapy, which is growing brachytherapy therapy to treat malignant growths. ISR has a market capitalization of $50.11 million with 141.92 million shares pending. The company has its headquarter in Richland, Washington, United States of America (USA).
